Abstract:Abstract Large pharmaceutical companies have withdrawn from antibiotic R&D because of the high risk of failure and because antibiotics are less profitable than other areas; small and medium-sized enterprises (SMEs), which now drive antibiotic R&D, face difficulty securing funding for preclinical and early clinical trials, and risk significant economic losses when launching new antibiotics. To reinvigorate the antibiotic pipeline, a holistic package of aligned incentives is required, which takes into account public health factors, improves return of investment while supporting SMEs, and considers operational feasibility including potential political, regulatory, legislative, industry and financial hurdles. This presentation will highlight the main options in this area. Improving access to effective antibiotics requires both short- and longer-term measures. Reducing regulatory administrative hurdles, engaging in good procurement practice, increasing joint purchasing efforts, and considering payment models that de-link revenue from sales can keep older (but effective) antibiotics on the market by ensuring their economic viability. Strengthening the mapping of production capacities and product availability can improve transparency and identify options for action, while stockpiling and strengthening manufacturing capacities within and outside of the EU can boost the supply chain itself. Concrete measures and their feasibility will be briefly presented. The EU has a major role to play by supporting antibiotic R&D and engaging with other international efforts to promote optimal deployment of incentives, by ensuring that the lack of access to appropriate and effective antibiotics is recognized as a threat to global health security, and by building on its relationships with international institutions to act as a facilitator in the global space towards ensuring synergies among existing structures, communicating the cost of inaction, and supporting national and regional initiatives. Speakers/Panelists Danilo Lo Fo Wong Division of Country Health Programmes, WHO/Europe, Copenhagen, Denmark Malin Grape Ministry of Health and Social Affairs, Stockholm, Sweden Lieven De Raedt Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium

Improving equitable access for effective antibacterial: an ecosystem approach

Addressing Challenges in Antibiotic Access: Barriers, Implications and Strategies for Solution

Advancing global antibiotic research, development and access

Using Antibiotics Responsibly: Are We There Yet?

Challenges and opportunities for continued access to effective antibiotics - what role for the EU?

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance

Achieving sustainable access to antibiotics is more than just a last mile challenge

Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach

Antimicrobial resistance and the great divide: inequity in priorities and agendas between the Global North and the Global South threatens global mitigation of antimicrobial resistance

Communication strategies for improving public awareness on appropriate antibiotic use: Bridging a vital gap for action on antibiotic resistance

Addressing antimicrobial resistance in low and middle-income countries: overcoming challenges and implementing effective strategies

What are the challenges for antibiotic stewardship at the community level? An analysis of the drivers of antibiotic provision by informal healthcare providers in rural India

The challenge of antimicrobial resistance: What economics can contribute

Interventions to address antimicrobial resistance: an ethical analysis of key tensions and how they apply in low- income and middle-income countries

Perceptions of effective policy interventions and strategies to address antibiotic misuse within primary healthcare in India: A qualitative study

The language of antimicrobial and antibiotic resistance is blocking global collective action

Influences on use of antibiotics without prescription by the public in low- and middle-income countries: a systematic review and synthesis of qualitative evidence

Antibiotic resistance and a dire need for novel and innovative therapies: The impending crisis

Antibiotic stewardship from a decision-making, behavioral economics, and incentive design perspective

The Production of Antibiotics Must Be Reoriented: Repositioning Old Narrow-Spectrum Antibiotics, Developing New Microbiome-Sparing Antibiotics

Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward